抄録
Uremia therapy made possible in 1960's by Scribner has grown to sustain more than 200, 000 patients world wide at a cost in excess of $2 billion annually. Examination of the process by which physician and patient select treatment indicates that geographic, economic, physician and patient bias, and ethical pressures contribute to formulation of the decision. Recognition of these variables facilitates acceptance of evolutionary changes as they take place.
